Health Products

Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancer

· Published by Health Canada · Official notice

Details

Alert type: Public advisory
Category: Health products - Drugs
Product: Janus Kinase (JAK) inhibitors, including: Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq and Xeljanz/Xeljanz XR.
Issue: Health products - Labelling
What to do: Consult with your health care professional if you have concerns about the use of JAK inhibitors.
Audience: General public, Health professionals
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Brand NameAvailable FormulationsMedicinal Ingredients
RINVOQ15 mg and 30 mg extended-release tabletsupadacitinib
XELJANZ/ XELJANZ XR5 mg and 10 mg tablets
11 mg extended-release tablets
tofacitinib
JAKAVI5 mg, 10 mg, 15 mg and 20 mg tabletsruxolitinib
OLUMIANT2 mg tabletsbaricitinib
CIBINQO50 mg, 100 mg, and 200 mg tabletsabrocitinib
INREBIC100 mg capsulesfedratinib

Issue

The Canadian labelling for all Janus Kinase (JAK) inhibitors is being updated to include the risks of serious heart-related problems, fatal blood clots and cancer. This is being done as a precautionary measure. To date, Canadian labelling for the drugs Cibinqo, Inrebic, Olumiant, Rinvoq and Xeljanz/Xeljanz XR have been revised. Health Canada is working with the manufacturer of Jakavi to update its Canadian labelling.

JAK inhibitors are prescription drugs authorized for sale in Canada for various inflammatory disorders, certain blood cancers and graft-versus-host disease.

These labelling updates are the result of a number of safety reviews conducted by Health Canada. In 2020 and 2021, Health Canada assessed and confirmed the risks of serious heart-related problems, fatal blood clots, and cancer with Xeljanz/Xeljanz XR. The Department also assessed whether these risks would apply to Olumiant and Rinvoq, which are also used for inflammatory conditions. Based on these findings and how these drugs work, Health Canada cannot rule out these risks for other JAK inhibitors. Therefore, as a precautionary measure, Health Canada is working with manufacturers to ensure Canadian labelling of all JAK inhibitors includes these risks.

Health Canada will continue to monitor safety information on JAK inhibitors, as it does for all health products on the Canadian market, to identify and assess potential harms. The Department will take appropriate and timely action should new health risks be identified.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime